/
Immunology
Chronic Graft Versus Host Disease
22
Pipeline Programs↗
40
Active Trials↗
24
Companies Involved↗
Chronic Graft Versus Host Disease is an emerging landscape with 22 programs across 24 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Incyte, Abbisko Therapeutics Co, Ltd. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 212
Phase 36
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
18 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.
Analysis
Trial Status
122
clinical trials
Completed50 · 41%
Recruiting20 · 16%
Active, not recruiting15 · 12%
Terminated15 · 12%
Unknown status12 · 10%
Not yet recruiting4 · 3%
Other6 · 5%
Clinical Trials
Trial Activity
122 trials
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)